The Grk5 Knockout RAW 264.7 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the murine RAW 264.7 macrophage cell line, providing a genetic loss-of-function model for GRK5 (G protein-coupled receptor kinase 5). This product is supplied as a purified cell line in which the Grk5 gene has been disrupted by CRISPR/Cas9-mediated targeting, enabling sustained elimination of GRK5 protein expression. The knockout cell line is an ideal substrate for studying the multifaceted roles of GRK5 in immune cell signaling without the confounding effects of transient gene silencing. It is suitable for applications requiring a stable, homogeneous population of cells deficient in GRK5, including long-term functional assays and drug screening experiments. Researchers should note that the knockout is achieved through a general gene disruption strategy, and the cell line has not been validated for monoclonality or specific editing patterns.
The host cell line, RAW 264.7, is an Abelson murine leukemia virus-transformed macrophage line originating from BALB/c mice, which has been extensively characterized as a model for innate immunity, phagocytosis, and inflammatory signaling. These cells exhibit robust responsiveness to a variety of stimuli, including toll-like receptor agonists, chemokines, and cytokines, leading to the activation of key transcriptional programs that drive the expression of proinflammatory mediators. RAW 264.7 macrophages recapitulate many functional properties of primary macrophages, such as the ability to migrate in response to chemotactic gradients, internalize pathogens through phagocytosis, and orchestrate cytokine networks. Their genetic tractability and well-defined culture requirements have established them as a workhorse cell line for mechanistic studies of macrophage biology and for high-throughput screening of immunomodulatory compounds.
GRK5 is a member of the GRK family that phosphorylates activated G protein-coupled receptors (GPCRs), promoting the recruitment of ??-arrestin 1/2, which sterically interdicts G protein coupling and facilitates receptor internalization. In addition to its canonical role in GPCR desensitization, GRK5 engages in non-GPCR signaling modalities by directly interacting with I??B?? and NF-??B p65, thereby promoting NF-??B activation and the transcription of inflammatory genes such as TNF?? and IL-6. GRK5 is activated downstream of protein kinase C (PKC) and calcium/calmodulin, and it phosphorylates downstream targets including ERK1/2, JNK, and p38 MAP kinases, linking GPCR stimulation to broader cellular responses. In the context of macrophage biology, GRK5 forms complexes with PI3K?? and the actin cytoskeleton, influencing cell migration and chemokine receptor regulation. The knockout of Grk5 therefore abolishes GPCR desensitization, impairs ??-arrestin-mediated signaling, and reduces NF-??B-driven cytokine production, as summarized by the provided mechanistic data.
The loss of GRK5 in RAW 264.7 cells significantly alters macrophage function by disrupting the delicate balance of inflammatory signaling. Without GRK5, chemokine receptors fail to undergo proper desensitization and internalization, leading to aberrant chemotaxis and potentially dysregulated migration in gradients of CCL2, CXCL12, or other chemokines. Simultaneously, the attenuation of NF-??B activation dampens the expression of proinflammatory cytokines, which could impact both autocrine and paracrine signaling loops central to innate immune defense. This dual defect makes the Grk5 Knockout RAW 264.7 Cell Line a powerful tool for dissecting the contribution of GRK5 to pathogen-induced responses, inflammasome priming, and cross-talk between GPCR and Toll-like receptor pathways. The model also facilitates the study of GRK5-specific inhibitors and their effects on macrophage polarization and tissue homeostasis.
This knockout cell line supports a wide array of research applications, including detailed mechanistic studies of GPCR signaling and desensitization, analysis of the NF-??B pathway in the context of TNF?? and IL-6 production, and validation of GRK5 as a therapeutic target in inflammatory diseases, cancer, or cardiovascular disorders. Representative assays that can be performed with this model include Western blotting for GRK5 and phospho-ERK, RT-qPCR for Grk5 transcript levels, GPCR internalization assays, calcium mobilization measurements, NF-??B luciferase reporter assays, and ELISA-based quantification of secreted TNF?? and IL-6. Additional functional studies, such as Transwell migration assays, phagocytosis assays, and immunofluorescence imaging of ??-arrestin translocation, benefit from the stable knockout background. For further technical inquiries or to explore customized applications, please contact Ascent Research.
